June 9, 2025

To Whom It May Concern

Company Name: Sawai Group Holdings Co., Ltd.
Representative: Mitsuo Sawai
President and Representative Director
(Securities Code: 4887 Prime Market of Tokyo Stock Exchange)
Contact: Yasushi Kora
Deputy General Manager
Group Finance Department
(Telephone Number: +81-6-6105-5823)

Notice Regarding the Filing of a Final Appeal and the Petition for Acceptance of the Final Appeal

Sawai Group Holdings Co., Ltd. (hereinafter the "Company") hereby announces that Sawai Pharmaceutical Co., Ltd., (hereinafter "Sawai Pharmaceutical"), a consolidated subsidiary of the Company, has carefully examined the judgment in the appellate proceedings of a patent infringement lawsuit previously announced in the notice titled "Notice Regarding Court Ruling Lawsuit Filed Against the Company's Consolidated Subsidiary" dated May 27, 2025, and filed a final appeal and submitted a petition for acceptance of the final appeal on June 9, 2025. The details are as follows.

1. Background to the filing of a final appeal and the petition for acceptance of the final appeal

As stated in the notice titled "Notice Regarding Court Ruling Lawsuit Filed Against the Company's Consolidated Subsidiary" dated May 27, 2025, Sawai Pharmaceutical was granted a favorable judgment by the Tokyo District Court on March 30, 2021, recognizing its claim of non-infringement, in the patent infringement lawsuit concerning the use patent of Nalfurafine. However, the case was subsequently appealed to the IP High Court, which ruled against the Company's claim.

In response to this judgment, Sawai Pharmaceutical has filed a final appeal and submitted a petition for acceptance of the final appeal with the Supreme Court because the company believes that the judgment is totally unacceptable as it extremely disregards the company's claims in the lawsuit.

2. Outlook

We are presently conducting a thorough review of the impact of this matter on our financial performance. In the event that any information necessitating disclosure arises, we will promptly and appropriately inform our stakeholders.